Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infection with HCV genotype 2 or 3~* Had cirrhosis determination~* Prior treatment failure~* Screening laboratory values within defined thresholds~* Subject had not been treated with any investigational drug or device within 30 days of the screening visit~* Use of highly effective contraception methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Prior exposure to an direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase~* Pregnant or nursing female or male with pregnant female partner~* Current or prior history of clinical hepatic decompensation~* History of clinically significant illness or any other major medical disorder that may have interfered with subject treatment, assessment or compliance with the protocol~* Excessive alcohol ingestion or significant drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF+RBV+placebo (Type: EXPERIMENTAL): Participants were randomized to receive SOF+RBV for 12 weeks followed by placebo to match SOF plus placebo to match RBV for 4 weeks.
- SOF+RBV (Type: EXPERIMENTAL): Participants were randomized to receive SOF+RBV for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).